Dacomitinib is a targeted drug of several generations

Dacomitinib (Dacomitinib) is a targeted drug that is a second-generation irreversible EGFR tyrosine kinase inhibitor. Early clinical studies have shown that it is effective in non-small cell lung cancer. In the ARCHER Phase 1050 study, oral dacomitinib at 45 mg/day was superior to the first-generation reversible EGFR tyrosine kinase inhibitor gefitinib in improving progression-free survival and overall survival when used as first-line treatment.

There is no prospective evidence to support the use of dacomitinib as subsequent therapy in patients treated with chemotherapy or first-generation EGFR tyrosine kinase inhibitors (such as gefitinib and erlotinib). Dacomitinib has not demonstrated any benefit in patients with non-small cell lung cancer and its use should be limited to patients with known EGFR sensitizing mutations. Compared with first-generation EGFR inhibitors, dacomitinib is associated with increased toxicity of diarrhea, rash, stomatitis, and paronychia. In summary, dacomitinib is an important first-line drug in patients with EGFR-mutated non-small cell lung cancer, and toxicity in these patients can be well controlled.

The original drug of dacomitinib has been launched in China and has entered the scope of Class B medical insurance. The price of the common specification 15mg*30 tablets per box may be more than 1,000 yuan; the European version of dacomitiniboriginal drug sold overseas, the specification 45mg*30 tablets may be more than 20,000 yuan per box (the price may fluctuate due to exchange rates). Currently, there are cheaper generic drugs of dacomitinib sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 45mg*30 tablets produced by a Lao pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to exchange rate effects).